Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Longboard Pharmaceuticals, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/11/2023 8-K Quarterly results
08/23/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Longboard Pharmaceuticals Completes Enrollment of Phase 1b/2a PACIFIC Study Evaluating LP352 for the Treatment of Developmental and Epileptic Encephalopathies • Enrolled 52 participants with Developmental and Epileptic Encephalopathies into the PACIFIC Study • Participants have a broad range of DEEs including Lennox-Gastaut syndrome, Dravet syndrome, SCN2A-related epilepsies, CDKL5 deficiency disorder, among others • PACIFIC topline results remain on track for around year-end 2023 LA JOLLA, Calif., August 23, 2023 – Longboard Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has completed enrollment of its Phase 1b/2a clinical trial, the PACIFIC Stu..."
08/14/2023 EFFECT Form EFFECT - Notice of Effectiveness:
08/04/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "4275 Executive Square, Suite 950 La Jolla, CA 92037"
08/04/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/04/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results • LP352 Phase 1b/2a PACIFIC Study enrollment completion expected this summer with topline data expected around year-end 2023 • Ended second quarter 2023 with $63.0 million in cash, cash equivalents and investments; cash runway is expected to support operations into mid-2024 LA JOLLA, Calif., August 3, 2023 – Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2023. “We have made great progress in the first half of 2023 and look forward to completing enrollment for ..."
05/26/2023 4 Tiller Jane (Director) has filed a Form 4 on Longboard Pharmaceuticals, Inc.
Txns: Granted 12,500 options to buy @ $7.06, valued at $88.3k
05/26/2023 4 SEKHRI PAUL J (Director) has filed a Form 4 on Longboard Pharmaceuticals, Inc.
Txns: Granted 12,500 options to buy @ $7.06, valued at $88.3k
05/26/2023 4 SCHNEIDER PHILLIP M (Director) has filed a Form 4 on Longboard Pharmaceuticals, Inc.
Txns: Granted 12,500 options to buy @ $7.06, valued at $88.3k
05/26/2023 4 Lynch Casey (Director) has filed a Form 4 on Longboard Pharmaceuticals, Inc.
Txns: Granted 12,500 options to buy @ $7.06, valued at $88.3k
05/26/2023 4 Le Goff Corinne (Director) has filed a Form 4 on Longboard Pharmaceuticals, Inc.
Txns: Granted 12,500 options to buy @ $7.06, valued at $88.3k
05/26/2023 4 Aurentz Vincent (Director) has filed a Form 4 on Longboard Pharmaceuticals, Inc.
Txns: Granted 12,500 options to buy @ $7.06, valued at $88.3k
05/26/2023 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results • LP352 Phase 1b/2a PACIFIC Study topline data expected in fourth quarter 2023 • LP659 IND submitted to FDA after incorporating input from a pre-IND meeting; Phase 1 initiation of first in-human clinical study on track for second quarter 2023, with Phase 1 topline single-ascending dose data expected in fourth quarter 2023 • Ended first quarter 2023 with $76.1 million in cash, cash equivalents and investments; cash runway is expected to support operations into mid-2024 LA JOLLA, Calif., May 9, 2023 – Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a..."
04/19/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
03/27/2023 SC 13D/A PFIZER INC reports a 17.3% stake in LONGBOARD PHARMACEUTICALS, INC.
03/10/2023 SC 13G/A FMR LLC reports a 15% stake in LONGBOARD PHARMACEUTICALS INC
03/02/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/02/2023 10-K Annual Report for the period ended December 31, 2022
03/02/2023 8-K Quarterly results
Docs: "Longboard Pharmaceuticals Reports Full Year 2022 Financial Results and Key Corporate Initiatives • LP352 Phase 1b/2a PACIFIC Study remains on track to complete enrollment in the first half of 2023, with topline data expected in the second half of 2023 • LP659 Phase 1 initiation of first in-human clinical study on track for first half of 2023, with Phase 1 topline single-ascending dose data expected in the second half of 2023 • Ended 2022 with $67.6 million in cash, cash equivalents and investments; cash runway is expected to support operations into mid-2024 • Further strengthened institutional shareholder base by completing a follow-on public offering of common stock in February 2023 with gross proceeds of $23.0 million • Longboard to host conference call..."
02/14/2023 SC 13G/A HBM Healthcare Investments Ltd. reports a 10% stake in Longboard Pharmaceuticals, Inc.
02/14/2023 SC 13G/A Cormorant Asset Management, LP reports a 10% stake in Longboard Pharmaceuticals, Inc.
02/14/2023 SC 13G/A PRICE T ROWE ASSOCIATES INC reports a 11.1% stake in LONGBOARD PHARMACEUTICALS IN
02/10/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/10/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/10/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/09/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/08/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNDERWRITING AGREEMENT Dated: February 7, 2023 LONGBOARD PHARMACEUTICALS, INC. 5,000,000 Shares of Voting Common Stock UNDERWRITING AGREEMENT February 7, 2023 Evercore Group L.L.C. Cantor Fitzgerald & Co. as Representatives of the several Underwriters c/o Evercore Group L.L.C. 55 East 52nd Street 10055 c/o Cantor Fitzgerald & Co. 499 Park Avenue New York, New York 10022",
"4275 Executive Square, Suite 950 La Jolla, CA 92037"
02/08/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
02/07/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
02/07/2023 8-K Results of Operations and Financial Condition, Other Events  Interactive Data
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy